{"entity":{"id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","aka":["PADL1NK-005"],"tldr":"A phase 3 trial testing PF-08046054 in non-small-cell lung cancer, now recruiting.","summary":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT07144280, led by Pfizer, and recruiting on the registry. Official title: PADL1NK-005: A Randomised, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC). Planned enrolment is 680 participants (estimated). The study started in 2025-09-29 and primary completion is expected in 2028-03-10. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07144280","url":"https://clinicaltrials.gov/study/NCT07144280"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pf-08046054"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07144280","phase":"3","setting":"PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","sponsor":"Pfizer","participation":[{"nct":"NCT07144280","source":"https://clinicaltrials.gov/study/NCT07144280","fetchedAt":"2026-10-07T16:55:28.490Z","studySha256":"19579e2f89b4fc75a3ff29d1924510d2ea1e2d9ed2989ca060b54e694eca32b1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"Pfizer","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":680,"enrolmentType":"ESTIMATED","siteCount":449,"recruitingSiteCount":423,"countries":["Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","United Kingdom","United States"]}],"started":"2025-09-29","startedType":"actual","enrolled":680,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nsclc-4/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}